AbbVie Inc. (NYSE:ABBV) has a beta value of 0.67 and has seen 4.51 million shares traded in the last trading session. The company, currently valued at $247.97B, closed the last trade at $141.77 per share which meant it lost -$0.89 on the day or -0.62% during that session. The ABBV stock price is -24.08% off its 52-week high price of $175.91 and 25.54% above the 52-week low of $105.56. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.82 million shares traded. The 3-month trading volume is 5.53 million shares.
The consensus among analysts is that AbbVie Inc. (ABBV) is an Overweight stock at the moment, with a recommendation rating of 2.20. 1 analysts rate the stock as a Sell, while 1 rate it as Overweight. 8 out of 24 have rated it as a Hold, with 13 advising it as a Buy. 1 have rated the stock as Underweight. The expected earnings per share for the stock is $3.31.
AbbVie Inc. (NYSE:ABBV) trade information
Sporting -0.62% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 09/20/22 when the ABBV stock price touched $141.77 or saw a rise of 2.13%. Year-to-date, AbbVie Inc. shares have moved 4.70%, while the 5-day performance has seen it change 2.34%. Over the past 30 days, the shares of AbbVie Inc. (NYSE:ABBV) have changed -0.06%. Short interest in the company has seen 14.03 million shares shorted with days to cover at 2.22.
Wall Street analysts have a consensus price target for the stock at $159.25, which means that the shares’ value could jump 10.98% from current levels. The projected low price target is $135.00 while the price target rests at a high of $200.00. In that case, then, we find that the current price level is -41.07% off the targeted high while a plunge would see the stock lose 4.78% from current levels.
AbbVie Inc. (ABBV) estimates and forecasts
Figures show that AbbVie Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -11.42% over the past 6 months, with this year growth rate of 9.45%, compared to 10.10% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 9.20% and 29.70% for the next quarter. Revenue growth from the last financial year stood is estimated to be 6.20%.
13 analysts offering their estimates for the company have set an average revenue estimate of $14.64 billion for the current quarter. 12 have an estimated revenue figure of $15.28 billion for the next quarter concluding in Sep 2022.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 12.20% over the past 5 years. Earnings growth for 2022 is a modest 137.00% while over the next 5 years, the company’s earnings are expected to decrease by -0.57%.
AbbVie Inc. is expected to release its next earnings report between April 28 and May 02 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 5.64 at a share yield of 3.98%. The company’s dividend yield has gone up over the past 12 months.
AbbVie Inc. (NYSE:ABBV)’s Major holders
Insiders own 0.11% of the company shares, while shares held by institutions stand at 71.44% with a share float percentage of 71.52%. Investors are also buoyed by the number of investors in a company, with AbbVie Inc. having a total of 3,720 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 150.52 million shares worth more than $24.4 billion. As of Mar 30, 2022, Vanguard Group, Inc. (The) held 8.52% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 129.63 million shares as of Mar 30, 2022. The firm’s total holdings are worth over $21.01 billion and represent 7.34% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. As of Mar 30, 2022, the former fund manager holds about 2.89% shares in the company for having 51.07 million shares of worth $8.28 billion while later fund manager owns 38.69 million shares of worth $6.27 billion as of Mar 30, 2022, which makes it owner of about 2.19% of company’s outstanding stock.